CAS 1654820-87-7

1-((R)-3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2,3-dihydroxypropan-1-one

CAS : 1654820-87-7

1-((R)-3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2,3-dihydroxypropan-1-one

Degré de pureté : 99%

Masse moléculaire : 474.52g/mol

Ref: 54-OR1074583

Ibrutinib Impurity 3 (PCI-45227) (Mixture of Diastereomers)

CAS : 1654820-87-7

Formule : C₂₅H₂₆N₆O₄

Couleur et forme : White To Off-White Solid

Masse moléculaire : 474.52

Ref: 4Z-I-061006

Dihydrodiol Ibrutinib

Produit contrôlé

CAS : 1654820-87-7

Applications Dihydrodiol Ibrutinib is a metabolite of Ibrutinib (I124970). Ibrutinib is a highly selective Bruton’s tyrosine kinase (Btk) irreversible inhibitor.
References MacGlashan, D., et. al.: Int. Immunol., 11, 475 (2011)

Formule : C₂₅H₂₆N₆O₄

Couleur et forme : Neat

Masse moléculaire : 474.51

Ref: TR-D450250

Dihydrodiol ibrutinib

CAS : 1654820-87-7

Dihydrodiol ibrutinib is a tyrosine kinase inhibitor drug that has been shown to inhibit the growth of cancer cells by targeting the epidermal growth factor receptor. It can be used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Dihydrodiol ibrutinib inhibits wild-type mouse cyp3a4 and human cyp3a4, which are responsible for metabolizing this drug. This inhibition leads to an increase in the blood concentration of dihydrodiol ibrutinib, which is currently being studied as a potential treatment for autoimmune diseases. The IR spectroscopy studies show that dihydrodiol ibrutinib binds to tubule cells in the kidney, which may lead to renal toxicity. The FTIR spectroscopy also showed that this drug binds with trifluoroacetic acid (TFA) during sample preparation, which may affect its stability.

Formule : C₂₅H₂₆N₆O₄

Degré de pureté : Min. 95%

Masse moléculaire : 474.5 g/mol

Ref: 3D-ERC82087

Dihydrodiol Ibrutinib

CAS : 1654820-87-7

Formule : C₂₅H₂₆N₆O₄

Masse moléculaire : 474.52

Ref: ST-EA-CP-I20003

Dihydrodiol-Ibrutinib

CAS : 1654820-87-7

PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)

Formule : C₂₅H₂₆N₆O₄

Couleur et forme : Solid

Masse moléculaire : 474.521

Ref: TM-T36429